耐药性不断出现时代的抗菌药物研发
Antimicrobial development in the era of emerging resistance.
作者信息
Sorlozano Antonio, Carrasco Cristina, Cabeza Jose, Villegas Enrique, Gutierrez Jose
机构信息
Department of Microbiology, School of Medicine, Avda de Madrid 11, E-18012 Granada, Spain.
出版信息
Mini Rev Med Chem. 2009 Jul;9(8):938-55. doi: 10.2174/138955709788681564.
Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.
美国食品药品监督管理局目前正在研究的抗生素包括
法罗培南（用于治疗鼻窦炎、支气管炎和社区获得性肺炎）、达巴万星（用于治疗导管感染）、替加环素（用于治疗医院获得性肺炎）、奥利万星（用于治疗菌血症）、头孢洛林和伊克拉霉素（用于治疗肺炎）。此外，所有这些抗生素对皮肤和软组织感染也都有效。
Zotero 插件